You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search


The drug library provides access to information on over 100 cancer drugs available for use in Canada.

Displaying Drugs List

44 Items
Other Name(s): Zytiga® (Janssen)
Exceptional Access Program
  • abiraterone - Metastatic castrate-resistant prostate cancer, with specific criteria
Oct 2016
Other Name(s): Tecentriq™ (Hoffman-La Roche Limited)
Feb 2018
Other Name(s): Inlyta® (Pfizer)
Exceptional Access Program
  • aXitinib - Treatment in patients with metastatic renal cell carcinoma of clear cell histology as a second-line treatment, for patients (based on the mutual
    assessment of the treating physician and patient) who are unable to tolerate ongoing use of an effective dose of everolimus or who have a contraindication to everolimus
Apr 2016
Other Name(s): Casodex® (multiple brands available)
ODB - General Benefit
  • bicalutamide
Nov 2017
Other Name(s): Blenoxane® (multiple brands available)
Aug 2016
Other Name(s): Suprefact® (Sanofi-Aventis); Suprefact Depot® (Sanofi-Aventis); Suprefact Nasal Spray® (Sanofi-Aventis)
ODB - General Benefit
  • buserelin
Aug 2015
Other Name(s): Jevtana® (Sanofi-Aventis)
New Drug Funding Program
  • Cabazitaxel - Metastatic Castrate-Resistant Prostate Cancer
Jan 2018
Other Name(s): Xeloda® (multiple brands available)
ODB Limited Use
  • capecitabine - As part of the CAPOX (XELOX) regimen for the first-line and second-line treatment of metastatic colorectal, small bowel or appendiceal adenocarcinomas.
  • capecitabine - For adjuvant treatment of stage 3 or high risk stage 2* colon, small bowel or appendiceal adenocarcinomas in patients who have completed surgery (within three months), who would normally be candidates for adjuvant chemotherapy with 5FU/LV.
  • capecitabine - First-line treatment of patients with metastatic colorectal, small bowel and appendiceal adenocarcinomas in whom combination chemotherapy is not recommended.
  • capecitabine - Treatment of metastatic breast cancer where patients have progressed after prior chemotherapy
  • capecitabine - In combination with trastuzumab and cisplatin for the treatment of patients with HER2-positive metastatic adenocarcinoma of the stomach or gastro-esophageal junction who have not received prior anti-cancer treatment for their metastatic disease
  • capecitabine - Neo-adjuvant treatment of rectal cancer
  • capecitabine - In combination with a platinum-containing product and epirubicin for the treatment of advanced (non-resectable; either locally advanced or metastatic) gastric or gastro-esophageal junction cancer
  • capecitabine - As part of the CAPOX (XELOX) regimen for the treatment of adjuvant stage III and high risk stage II colorectal, small bowel or appendiceal adenocarcinomas.
Dec 2016
Other Name(s): Paraplatin AQ® (multiple brands available)
Aug 2016
Other Name(s): Platinol AQ® (multiple brands available)
Aug 2016
Other Name(s): Procytox® (Baxter)
ODB - General Benefit
  • cyclophosphamide - oral tablets
Nov 2017
Other Name(s): Firmagon® (Ferring)
ODB - General Benefit
  • degarelix
Mar 2013